FNKV (Facultni Nemocnice Kralovske Vinohrady)
Welcome,         Profile    Billing    Logout  
 2 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mocikova, Heidi
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
241
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
11/25
11/25
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting
2
82
Europe, US, RoW
brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone
Seagen, a wholly owned subsidiary of Pfizer
Peripheral T-cell Lymphoma
05/24
12/25
CLSGMCLPOLA, NCT04913103: Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL

Not yet recruiting
2
21
RoW
Polatuzumab vedotin, Polivy, Bendamustine Hydrochloride, Bendamustine Accord, Bendamustine Glenmark, Bendamustine KABI, Rituximab, Mabthera, Rixathon, Truxima
Czech Lymphoma Study Group
Lymphoma, Mantle-Cell
08/26
08/27
NU22-03-00182, NCT06263530: Prognostic Significance of ctDNA in HL

Recruiting
N/A
500
RoW
Interni hematologicka klinika FNKV, Charles University, Czech Republic, General University Hospital, Prague, University Hospital Olomouc, University Hospital Hradec Kralove, University Hospital, Motol
Prognostic Cancer Model
12/23
12/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mocikova, Heidi
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
241
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
11/25
11/25
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting
2
82
Europe, US, RoW
brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone
Seagen, a wholly owned subsidiary of Pfizer
Peripheral T-cell Lymphoma
05/24
12/25
CLSGMCLPOLA, NCT04913103: Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL

Not yet recruiting
2
21
RoW
Polatuzumab vedotin, Polivy, Bendamustine Hydrochloride, Bendamustine Accord, Bendamustine Glenmark, Bendamustine KABI, Rituximab, Mabthera, Rixathon, Truxima
Czech Lymphoma Study Group
Lymphoma, Mantle-Cell
08/26
08/27
NU22-03-00182, NCT06263530: Prognostic Significance of ctDNA in HL

Recruiting
N/A
500
RoW
Interni hematologicka klinika FNKV, Charles University, Czech Republic, General University Hospital, Prague, University Hospital Olomouc, University Hospital Hradec Kralove, University Hospital, Motol
Prognostic Cancer Model
12/23
12/27

Download Options